- Home
- SLI vs KROS Comparison
SLI vs KROS Comparison
Compare SLI & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLI
- KROS
- Stock Information
- Founded
- SLI 1998
- KROS 2015
- Country
- SLI Canada
- KROS United States
- Employees
- SLI N/A
- KROS N/A
- Industry
- SLI Major Chemicals
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- SLI Industrials
- KROS Health Care
- Exchange
- SLI Nasdaq
- KROS Nasdaq
- Market Cap
- SLI 595.8M
- KROS 565.0M
- IPO Year
- SLI N/A
- KROS 2020
- Fundamental
- Price
- SLI $3.78
- KROS $15.22
- Analyst Decision
- SLI Strong Buy
- KROS Buy
- Analyst Count
- SLI 3
- KROS 14
- Target Price
- SLI $5.42
- KROS $20.56
- AVG Volume (30 Days)
- SLI 8.0M
- KROS 1.1M
- Earning Date
- SLI 11-10-2025
- KROS 11-06-2025
- Dividend Yield
- SLI N/A
- KROS N/A
- EPS Growth
- SLI N/A
- KROS N/A
- EPS
- SLI N/A
- KROS 0.47
- Revenue
- SLI N/A
- KROS $232,844,000.00
- Revenue This Year
- SLI N/A
- KROS $6,657.47
- Revenue Next Year
- SLI N/A
- KROS N/A
- P/E Ratio
- SLI N/A
- KROS $32.70
- Revenue Growth
- SLI N/A
- KROS 85820.30
- 52 Week Low
- SLI $1.08
- KROS $9.12
- 52 Week High
- SLI $6.40
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- SLI 44.62
- KROS 49.86
- Support Level
- SLI $3.68
- KROS $14.77
- Resistance Level
- SLI $3.99
- KROS $15.47
- Average True Range (ATR)
- SLI 0.42
- KROS 0.69
- MACD
- SLI -0.14
- KROS 0.01
- Stochastic Oscillator
- SLI 9.34
- KROS 70.74
About SLI Standard Lithium Ltd.
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company is focused on the exploration and development of the Arkansas Lithium Project, which is located in south-central Arkansas. Its other projects comprise the Lanxess Project, and Bristol Dry Lake Project.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.